van Zyl R L, Havlik I, Monteagudo F S
Department of Experimental and Clinical Pharmacology, University of the Witwatersrand, Medical School, Parktown, Johannesburg, South Africa.
J Antimicrob Chemother. 1992 Sep;30(3):273-8. doi: 10.1093/jac/30.3.273.
The emergence of drug resistant malaria has prompted an intensified search for new antimalarials or combinations of such drugs. Iron chelating agents may represent a new approach to antimalarial treatment and could possibly be used in combination with classical antimalarials. Plasmodium falciparum (FCR-3) strain used at a 1% haematocrit, was subjected to various combinations of the classic antimalarials (chloroquine, pyrimethamine and quinine) and iron chelating agents (desferrioxamine and 2,2'-bipyridyl) in vitro. Tritiated hypoxanthine incorporation was used to determine the growth of the malarial parasites. The iron chelating agents and classic antimalarials when tested alone were found to inhibit the growth of the late stages of the parasite. The combination of the classic antimalarials and iron chelating agents resulted in additive effects on the in-vitro growth of P. falciparum.
耐药性疟疾的出现促使人们加紧寻找新的抗疟药物或此类药物的组合。铁螯合剂可能代表了一种抗疟治疗的新方法,并有可能与传统抗疟药物联合使用。在体外,将恶性疟原虫(FCR-3株)以1%的血细胞比容进行处理,使其接触传统抗疟药物(氯喹、乙胺嘧啶和奎宁)和铁螯合剂(去铁胺和2,2'-联吡啶)的各种组合。用氚标记的次黄嘌呤掺入法来测定疟原虫的生长情况。单独测试时,发现铁螯合剂和传统抗疟药物可抑制疟原虫后期的生长。传统抗疟药物与铁螯合剂的组合对恶性疟原虫的体外生长产生了相加作用。